Hígado graso no alcohólico: ¿un componente inflamatorio del síndrome metabólico?

  • Johan Almarza Centro de Investigaciones Endocrino-Metabólicas Dr. Félix Gómez
Palabras clave: hígado graso, síndrome metabólico, estrés oxidativo

Resumen

Objetivo: integrar los componentes que relacionan la insulinorresistencia en el desarrollo de hígado graso no alcohólico y los mecanismos moleculares implicados en la fisiopatología, los métodos diagnósticos y las implicaciones clínicas. Materiales y métodos: se realizó una búsqueda sistemática de artículos desde 1990 a 2010 en el periodo comprendido entre octubre de 2009 a diciembre de 2010, seleccionados de bases de datos internacionales PubMed y en los servicios ScienceDirect y Ovid; la búsqueda de información relacionada con América Latina, incluyendo Colombia, y Venezuela, se efectuó en Lilacs y Scielo. Para la elección de los términos se utilizó el Medical Subject Headings (Mesh) y los vocabularios controlados de cada uno de los servicios consultados. Resultados y conclusiones: los mediadores inflamatorios (adipoquinas), oxidativos (especies reactivas de oxígeno) y metabólicos (ácidos grasos libres) responsables de la historia natural del SM están relacionados con el desarrollo del Hígado Graso no Alcohólico (HGNA), por lo tanto la identificación de este componente patológico, mediante lo métodos bioquímicos y ecográficos pertinentes, es de suma importancia. La pérdida gradual de peso, el aumento de la actividad física más las modificaciones dietarias que aumentan la expresión de enzimas peroxisomales de la beta oxidación de ácidos grasos, y previenen su posterior acumulación citoplasmática.
|Resumen
= 928 veces | PDF
= 462 veces|

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Johan Almarza, Centro de Investigaciones Endocrino-Metabólicas Dr. Félix Gómez
Centro de Investigaciones Endocrino-Metabólicas Dr. Félix Gómez. Maracaibo- Venezuela.

Citas

Cornier M, Dabelea D, Hernández T, Lindstrom R, Steig A, Stob N, et al. The metabolic syndrome. Endocrinol Rev. 2008;29: 777-822.

Bagry H. Metabolic syndrome and insulin resistance. Anesthesiology. 2008;108:506-23.

Eckel R. The metabolic SM. Lancet. 2005;365:1415-28.

Roden. Mechanisms of disease:hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2:335-48.

Mendez-Sánchez N, Chavez N, Uribe M. Hígado graso no alcohólico: nuevos conceptos. Investigación Clínica. 2004;56:72-82.

Ludwig J, McGill DB, Lindor KD. Review: nonalcoholic steatohepatitis. J Gastro Hepatol. 1997;12:398-03.

Castera L. Non-invasive diagnosis of steatosis and fibrosis. Diabetes Metab. 2008;34:674-79.

Mehta S, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol. 2009;50:36-41.

Poynard T, Muntenau M, Morra R, Ngo Y, Imbert-Bismut F, Thabut D. Methodological aspects for the interpretation of liver fibrosis non-invasive biomarkers: a 2008 update. Gastroenterol Clin Biol. 2008;32:8-21.

Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50:1-3.

Lemoine S. Definition and natural history of metabolic steatosis clinical aspects of NAFLD, NASH and cirrosis. Diabetes Metab. 2008;34:634-7.

Brent A. Neuschwander-Tetri. Fatty liver and the metabolic SM. Curr Opin Gastroenterol. 2007;23:193-8.

Tordjmana J, Clémenta M, Guerre-Milloa K. Adipose tissue inflammation and liver pathology in human obesity. Diabetes Metab. 2008;34 658-63.

Lafontan M, Girard J. Impact of visceral adipose tissue on liver metabolism. Part I: Heterogeneity of adipose tissue and functional properties of visceral adipose tissue. Diabetes Metab. 2008;34:317-27.

Girard J, Lafontan M. Impact of visceral adipose tissue on liver metabolism and insulin resistance. Part II: Visceral adipose tissue production and liver metabolism. Diabetes Metab. 2008;34:439-45.

Mutch DM, Clément K. Genetics of human obesity. Best Pract Res Clin Endocrinol Metab. 2006;20:647-64.

Tillotson J. America’s obesity: conflicting public policies, industrial economic development, and unintended human consequences. Annu Rev Nutr. 2004;24:617-43.

Mantena S. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol and obesity-induced fatty liver diseases. Free Radic Biol Med. 2008;44:1259-72.

Perlemuter G, Bigorgne A, Cassard-Doulcier A, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab. 2007;3:458-69.

Caldwell SH, Chang CY, Nakamoto RK, Krugner-Higby L. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:595-617.

Postica C, Girarda J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab. 2008;34:643-8.

Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005;36:232-40.

Voshol PJ, Haemmerle G, Ouwens DM, Zimmermann R, Zechner R, Teusink B, et al. Increased hepatic insulin sensitivity together with decreased hepatic triglyceride stores in hormone-sensitive lipase-deficient mice. Endocrinology. 2003;144:3456-62.

Park SY, Kim HJ, Wang S, Higashimori T, Dong J, Kim YJ. Hormone-sensitive lipase knockout mice have increased hepatic insulin sensitivity and are protected from short-term diet-induced insulin resistance in skeletal muscle and heart. Am J Physiol Endocrinol Metab. 2005;289:30-9.

Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91: 4753-61.

Videla A, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non alcoholic fatty liver disease. Trends Mol Med. 2006;12:555-8.

Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, et al. Nonalcoholic fatty liver disease:predisposing factors and the role of nutrition. J Nutr Biochem. 2007;18:184-95.

Zulet A. Biomarcadores del estado inflamatorio, nexo de unión con la obesidad y complicaciones asociadas. Nutri Hosp. 2007;22:511-27.

Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31.

O’shea J, Gadina M, Schreiber R. Cytokine signaling in 2002: New surprises in the Jak/Stat pathway. Cell. 2002;109:S121-S31.

O’shea J, Murray P. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28:477-87.

Wullaert A, Van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor kappa beta: effects on liver homeostasis and beyond. Endocrinol Rev. 2007;28:365-86.

Strasser H, McDunn A, Swanson J. Cell death. N Engl J Med. 2009;361:1570-83.

Aggarwal B. Signalling pathways of the TNF super family: a double-edged sword. Nat Rev Immunol. 2003;3:745-56.

Peraldi P, Hotamisligil. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55TNF receptor and activation of sphingomyelinase. J Biol Chem. 1996;271:13018-22.

Liu LM, Spelleken K, Rohring H, Hauner. Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes:implication of the p80 tumor necrosis factor receptor. Diabetes. 1998;47:515-22.

Uysal K. Functional analysis of tumor necrosis factor (TNF) receptors in TNFalpha- mediated insulin resistance in genetic obesity. Endocrinology. 1998;139:4832-8.

Sethi J, Uysal S Wiesbrock L. Characterization of receptor-specific TNF-alpha functions in adipocyte cell lines lacking type 1 and 2 TNF receptors. FEBS Lett. 2000;469:77-82.

Hotamisligil GS, Arner P, Atkinson RL. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes. 1997;46:451-5.

Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH:TNF-alpha or adiponectin? Hepatology. 2004;40:46-54.

Marra F, Aleffi S, Bertolani C, Petrai I, Vizzutti F. Adipokines and liver fibrosis. Eur Rev Med Pharmacol Sci. 2005;9:279-84.

Musso G, Gambino R, Biroli G, Carello M, Faga E, Pacini G. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2005;100:2438-46.

Trappoliere F, Loguercio C. Treatment of patients with non-alcoholic fatty liver disease: Current views and perspectives. Digest Liver Dis. 2006;38:789-80.

Lingvay I, Raskin P, Szczepaniak L. Effect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications. 2007;21:137-42.

Capeau J. Insulin resistance and steatosis in humans. Diabetes Metab. 2008;34:649-57.

Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone- treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89:200-306.

Tiikkainen M, Hakkinen A, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004;53:2169-76.

Machado M, Cortez-Pinto H. Non-alcoholic fatty liver disease and insulin resistance. Eur J Gatroenterol Hepatol. 2005;17:823-6.

Ten S, Maclaren N. Insulin resistance syndrome in children. J Clin Endocrinol Metabol. 2004;89:2596-639.

Festi DA, Sacco T, Bondi M. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obesity Rev. 2004;5:27-42.

Angulo P, Lindor K. Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:797-810.

Hughes T. Emerging therapies for metabolic diseases: the focus is on diabetes and obesity. Curr Opin Chem Biol. 2009;13:1-6.

Publicado
2011-07-10
Cómo citar
Almarza, J. (2011). Hígado graso no alcohólico: ¿un componente inflamatorio del síndrome metabólico?. Perspectivas En Nutrición Humana, 12(2), 163-175. Recuperado a partir de https://revistas.udea.edu.co/index.php/nutricion/article/view/9571
Sección
Artículos de Revisión